Latest filing published 17 May 2023 for Reata Pharmaceuticals INC, €23k.
Filing timeline
BuySaleInsider track record
Samina Khan: trading record in brief
Samina Khan discloses dealings in Reata Pharmaceuticals Inc to SEC (Form 4). In total, 9 filings cover trades dated from 3 January 2023 to 16 May 2023.
Every open-market trade on record is a sale: 7 sales worth €2.6M. Outside the open market, there are 1 share grant and 1 option exercise.
The record was last updated on 17 May 2023 with an open-market sale (€26k) in Reata Pharmaceuticals Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Samina Khan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 288 shares@ US$85.322.3% of flowClass A common stockSEC:0001209191-23-030192:0
- 3,961 shares@ US$83.4631.8% of flowClass A common stockSEC:0001209191-23-017220:0
- 25,000 shares@ US$27.3265.9% of flowClass A common stockSEC:0001209191-23-016306:0
- 11,756 shares0Class A common stockSEC:0001209191-23-001008:0
4 of 4 declarations
